Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 9/20 | 0.42 |
| ▸ | CA2 | P00918 | 9/20 | 0.42 |
| ▸ | CA9 | Q16790 | 9/20 | 0.42 |
| ▸ | CA1 | P00915 | 8/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 2/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30014737 | 0.81 | CA12 (0.55) | CA12CA2CA9CA1CA14 | |
| SCHEMBL30508939 | 0.81 | NAPRT (0.45) | CA12CA2CA9CA1CA14 | |
| SCHEMBL30014015 | 0.79 | FTO (0.46) | CA12CA2CA9CA1CA14 | |
| SCHEMBL2646684 | 0.77 | CA12 (0.39) | CA12CA2CA9CA1CA14 | |
| SCHEMBL19144940 | 0.77 | L3MBTL1 (0.44) | CA12CA2CA9CA1CA14 | |
| SCHEMBL23665029 | 0.75 | CA12 (0.38) | CA12CA2CA9CA1CA14 | |
| SCHEMBL30050575 | 0.75 | KDM4E (0.47) | CA12CA2CA9CA1CA14 | |
| SCHEMBL21768460 | 0.75 | CA12 (0.43) | CA12CA2CA9CA1CA14 | |
| SCHEMBL30784405 | 0.75 | PTGS2 (0.42) | CA12CA2CA9CA1CA14 | |
| SCHEMBL18230499 | 0.75 | KDM4E (0.47) | CA12CA2CA9CA1CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1702919-B1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-7728025-B2 | 2-heteroaryl-substituted benzimidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1702919-A1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | GCK, GCKR, HK1 | CA12 3942/4885CA2 893/4885CA9 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.